Modified baculoviruses housing human genes are protected from serum inactivation by encapsulation and coated onto a medical devices such as a cardiac stent or formulated into a cream. NOTE Gene expression is TRANSIENT, and baculoviruses are very safe.
Gene-Delivering cardiac stents
Current paradigm is that drug-eluting stents ONLY react to the consequences of endothelial cell damage – NOT FIX THE PROBLEM. MangoGen’s technology is designed to rapidly induce the re-growth of a fully functional endothelium, preventing in-stent re-stenosis and possibly scar tissue formation.
There is a need for new effective and safe topical creams to accelerate wound healing (e.g. surgical wounds and ulcers). MangoGen’s gene-delivery approach is TARGETED to the cells in and around the wound, inducing rapid
MangoGen’s patented technology applied onto a suture will target and deliver genes in and around the wound that will prevent scar tissue formation.
Three Components of MangoGen's Patented Platform Technology include: (1) Insertion of human gene(s) in to a baculovirus; (2) Baculoviral protection from serum inactivation by encapsulation; and (3) Coating onto a suitable matrix, or formulated into a cream/gel. MangoGen is developing gene-delivery products in the following -
Current Paradigm (Drug-Eluting Stents) - Only react to consequences of wound damage. Global market value US$11 billion
Few approved treatments; Urgent clinical & economic needs. Global market size US$17 billion (2017)
Urgent need for better treatments. Increasing problem - number of diabetics is dramatically increasing. Global market size US$5 billion
Preventing scar tissue formation - after surgery, plastic surgery or accident - improve outcomes. Global market US$ 9.4 billion (2017)